Human Recombinant IGFBP7 (from E. coli)

Supplier: PeproTech

AF350095UG AF3500925UG AF35009250UG AF350091MG AF35009500UG AF35009100UG
10771-774EA 182.81 CAD
10771-774 10771-776 10771-780 10771-784 10771-782 10771-778
Human Recombinant IGFBP7 (from E. coli)
Proteins and Peptides
IGF-BPs control the distribution, function and activity of IGFs in various cell tissues and body fluids.  Currently, there are seven named IGF-BPs that form high affinity complexes with both IGF-I and IGF-II.  IGF-BP7 is expressed in a wide range of normal human tissues, and it generally shows reduced expression in cancer cell lines of prostate, breast, colon, and lung origin.  It plays a role in skeletal myogenesis by binding to IGF in a manner that inhibits IGF-induced differentiation of skeletal myoblasts, without affecting IGF-induced proliferation.  Additionally, IGF-BP7 suppresses growth and colony formation of prostate and breast cancer cell lines through an IGF-independent mechanism, which causes a delay in the G1 phase of the cell cycle and increased apoptosis. Recombinant Human IGF-BP7 is a 26.4 kDa protein consisting of 256 amino acid residues.Manufactured using all Animal-Free reagents.

  • Carrier free
  • Animal-free

SSSDTCGPCE PASCPPLPPL GCLLGETRDA CGCCPMCARG EGEPCGGGGA GRGYCAPGME CVKSRKRRKG KAGAAAGGPG VSGVCVCKSR YPVCGSDGTT YPSGCQLRAA SQRAESRGEK AITQVSKGTC EQGPSIVTPP KDIWNVTGAQ VYLSCEVIGI PTPVLIWNKV KRGHYGVQRT ELLPGDRDNL AIQTRGGPEK HEVTGWVLVS PLSKEDAGEY ECHASNSQGQ ASASAKITVV DALHEIPVKK GEGAEL

Verified by N-terminal and Mass Spectrometry analyses (when applicable).

Ordering information: For research use only. Not for use in diagnostic or therapeutic procedures.
Order Now

Learn more

About VWR

Avantor is a vertically integrated, global supplier of discovery-to-delivery solutions for...

Learn more About VWR